Zydus Cadila acquires Etna Biotech
This article was originally published in Scrip
Executive Summary
Zydus Cadilahas acquired Etna Biotech, a subsidiary of the Dutch biopharmaceutical company Crucell, for an undisclosed sum. Zydus expects the deal to catapult it to the forefront of innovation in vaccine R&D, and is the first acquisition by Zydus of a research firm.